Gout Therapeutics Market to Reach USD 6.2 Billion by 2034

Pune, India, November 2025 - According to the latest report from Exactitude Consultancy, the Global Gout Therapeutics Market is projected to grow from USD 3.1 billion in 2024 to USD 6.2 billion by 2034, registering a steady CAGR of 7.1% during the forecast period (2025-2034). Rising gout prevalence, the growing adoption of biologic therapies, and the integration of AI-driven drug discovery platforms are fueling significant growth in this segment.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/75888

Key Takeaways
• Market Size 2024: USD 3.1 Billion
• Forecast 2034: USD 6.2 Billion
• CAGR (2025-2034): 7.1%
• Key Drug Classes: NSAIDs, Colchicine, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosuric Agents, Biologic Therapies
• Key Drivers: Rising Prevalence of Gout, Personalized Medicine Advances, Growing Biologic Pipeline, Increasing Healthcare Access
• Top Regions: North America, Europe, Asia Pacific
• Leading Players: Takeda, Horizon Therapeutics (Amgen), AstraZeneca, Novartis, Teijin Pharma, GlaxoSmithKline (GSK), Selecta Biosciences, Johnson & Johnson, Ironwood Pharmaceuticals, LG Chem

Market Story
Gout, a painful and chronic form of inflammatory arthritis, continues to affect millions globally. Modern therapeutic innovation is transforming treatment-from traditional urate-lowering drugs to targeted biologic and monoclonal antibody therapies that address the root cause of hyperuricemia.

The market's evolution is propelled by a rise in lifestyle-related risk factors such as obesity, alcohol consumption, and hypertension. Meanwhile, biotech companies are developing novel uricase-based biologics and AI-powered molecule screening to identify effective, safer options for refractory gout patients. Government reimbursement programs and increasing access to specialty care further strengthen growth prospects.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/75888/gout-therapeutics-market

Segmentation Overview
• By Drug Type:
NSAIDs, Colchicine, Corticosteroids, Xanthine Oxidase Inhibitors (Allopurinol, Febuxostat), Uricosuric Agents (Probenecid, Lesinurad), Biologic Therapies (Pegloticase, SEL-212)

• By Disease Type:
Acute Gout, Chronic Gout, Tophaceous Gout
• By Route of Administration:

Oral, Injectable, Intravenous
• By Distribution Channel:
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

• By Region:
North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Recent Developments
• Horizon Therapeutics (Amgen): Expanded global reach for Krystexxa® (pegloticase) with combination biologic protocols for refractory gout.
• Selecta Biosciences: Advanced clinical trials for SEL-212, a novel immunomodulatory enzyme therapy targeting chronic hyperuricemia.
• AstraZeneca: Continued development of Lesinurad combinations for uric acid management.
• Takeda: Strengthened its gout research pipeline via strategic collaborations with AI drug-discovery firms.
• Novartis: Invested in next-generation IL-1 inhibitors for inflammation modulation in severe gout cases.

Expert Insight
"Biologic therapies and personalized medicine are redefining gout treatment paradigms. With AI accelerating drug discovery, we're entering an era where gout management will be targeted, predictive, and far more effective," said Anurag Tiwari, Senior Healthcare Analyst at Exactitude Consultancy.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=75888

Market Drivers
1. Rising Gout Incidence: The global prevalence of gout exceeds 3% of the adult population, primarily linked to lifestyle and diet.
2. Shift Toward Biologics: Monoclonal antibodies and uricase-based biologics offer better efficacy for treatment-resistant patients.
3. AI & Precision Medicine: Machine learning models are optimizing molecule design, clinical trial targeting, and patient response prediction.
4. Improved Awareness & Screening: Early diagnosis and disease education programs drive faster treatment adoption.
5. Regulatory Support: Expedited FDA pathways for innovative gout therapies encourage faster commercialization.

Forecast & Regional Insights
North America dominates the gout therapeutics landscape, supported by advanced R&D, strong biologic adoption, and favorable insurance coverage. Europe follows, with increasing biologic approvals and national arthritis programs. Asia Pacific is emerging as the fastest-growing region due to rising awareness, increasing obesity rates, and expanded access to specialty drugs in China and India.

By 2034, next-generation biologics and combination therapies will redefine treatment standards, enabling long-term remission and improved patient outcomes globally.

Conclusion
The Gout Therapeutics Market is transitioning from conventional pain relief toward precision-targeted, disease-modifying biologic treatments. The next decade will see breakthroughs in AI-assisted drug discovery, enhanced clinical trial efficiency, and global access to advanced gout care-transforming how chronic inflammatory diseases are managed worldwide.

This report is also available in the following languages : Japanese (痛風治療薬市場), Korean (통풍 치료제 시장), Chinese (痛风治疗市场), French (Marché des traitements contre la goutte), German (Markt für Gichttherapeutika), and Italian (Mercato terapeutico della gotta), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/75888

Our More Reports:

Digital Therapeutics (DTx) Market
https://exactitudeconsultancy.com/reports/7904/digital-therapeutics-dtx-market

Disposable Medical Device Sensors Market
https://exactitudeconsultancy.com/reports/8040/disposable-medical-sensors-device-market

Cell Isolation/Cell Separation Market
https://exactitudeconsultancy.com/reports/14751/cell-isolation-cell-separation-market

Biologics Safety Testing Market
https://exactitudeconsultancy.com/reports/28396/biologics-safety-testing-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.